The UK's National Institute for Health and Care Excellence has approved Enhertu for use within England's National Health Service, with around 1,000 women with advanced breast cancer expected to benefit each year.

The decision has drawn criticism over the cost of the UK–US drug agreement, and lawmakers are calling for an investigation by the National Audit Office.